Skip to content
JournalsWorldThe Global Research Discovery Platform
Login Sign Up
SCHOLARLY PUBLICATION

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

Thorsten Kuehn, Ingo Bauerfeind, Tanja Natascha Fehm, Barbara Fleige, Maik Hausschild, Gisela Helms, Annette Lebeau, Cornelia Liedtke, Gϋnter von Minckwitz, Valentina Nekljudova, Sabine Schmatloch, Peter Schrenk, Annette Staebler, Michael Untch

📖 The Lancet Oncology → 📅 2013-05-14 🔗 DOI: 10.1016/s1470-2045(13)70166-9
View Journal Profile → View Official Paper ↗

📄 Abstract

The abstract has not yet been added. Use the official source link for the complete publication record.

🔬 Related Research Papers

The Lancet Oncology

De-novo and acquired resistance to immune checkpoint targeting

Nicholas L. X. Syn, Michele W.L. Teng et al. 2017-12-01 · Read paper → The Lancet Oncology

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

Helena Linardou, Issa J Dahabreh et al. 2008-09-18 · Read paper → The Lancet Oncology

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

Thomas Bachelot, Gilles Romieu et al. 2012-11-01 · Read paper → The Lancet Oncology

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim S. Fizazi et al. 2013-01-08 · Read paper → The Lancet Oncology

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

Robert John Motzer, Bernard J. Escudier et al. 2013-04-17 · Read paper → The Lancet Oncology

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz et al. 2016-10-22 · Read paper → The Lancet Oncology

Increasing incidence of colorectal cancer in Asia: implications for screening

Joseph J.�Y. Sung, James Lau et al. 2005-11-01 · Read paper → The Lancet Oncology

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Takashi Seto, Terufumi Kato et al. 2014-08-27 · Read paper → The Lancet Oncology

Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study

Brian P O'Sullivan, Shao Hui Huang et al. 2016-02-27 · Read paper → The Lancet Oncology

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

Robert I. Haddad, Anne O’Neill et al. 2013-02-12 · Read paper → The Lancet Oncology

Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis

Alex J. Mitchell, David W Ferguson et al. 2013-06-04 · Read paper → The Lancet Oncology

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp et al. 2014-07-14 · Read paper →